{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:40:10Z","timestamp":1756392010534,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Natural Science Foundation of Guangdong Province","award":["2022A1515012509"],"award-info":[{"award-number":["2022A1515012509"]}]},{"name":"The Project of Guangdong clinical medical research center of digestive diseases","award":["2020B1111170004"],"award-info":[{"award-number":["2020B1111170004"]}]},{"name":"National Key Clinical Discipline and the program of Guangdong Provincial Clinical Research Center for Digestive Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03281-w","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T14:58:13Z","timestamp":1756047493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel immune-metabolic prognostic model stratifies survival and personalizes therapy in hepatocellular carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Zejin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taijun","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengrui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"key":"3281_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","author":"LS Rebecca","year":"2024","unstructured":"Rebecca LS, Angela NG, Ahmedin J. Cancer statistics, 2024. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"3281_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.10.001","author":"C-R Saranya","year":"2021","unstructured":"Saranya C-R, Paul BF, Devanand S. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.001.","journal-title":"Adv Cancer Res."},{"key":"3281_CR3","doi-asserted-by":"publisher","unstructured":"Ming Ren T, Evelyn Yi Ting W, Sunny Hei W, et al. Global epidemiology and genetics of hepatocellular carcinoma. 2023. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.033.","DOI":"10.1053\/j.gastro.2023.01.033"},{"key":"3281_CR4","doi-asserted-by":"publisher","unstructured":"Prashanth R, Tagore S, Pradhyumna M, et al. Update in global trends and aetiology of hepatocellular carcinoma. 2018. https:\/\/doi.org\/10.5114\/wo.2018.78941.","DOI":"10.5114\/wo.2018.78941"},{"key":"3281_CR5","doi-asserted-by":"publisher","unstructured":"Ender Gunes Y, Erkan O, Emrah K, et al. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. 2016. https:\/\/doi.org\/10.1016\/s1499-3872(16)60097-8.","DOI":"10.1016\/s1499-3872(16)60097-8"},{"key":"3281_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10084-4","author":"W Yu","year":"2023","unstructured":"Yu W, Baocheng D. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023. https:\/\/doi.org\/10.1007\/s10555-023-10084-4.","journal-title":"Cancer Metastasis Rev"},{"key":"3281_CR7","doi-asserted-by":"publisher","unstructured":"Kelley R, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. 2021;39(27):2991\u20133001. https:\/\/doi.org\/10.1200\/jco.20.03555.","DOI":"10.1200\/jco.20.03555"},{"key":"3281_CR8","doi-asserted-by":"publisher","unstructured":"Jin L, Qing-Bo W, Yu-Bo L, et al. Tumor-associated lymphatic vessel density is a reliable biomarker for prognosis of esophageal cancer after radical resection: a systemic review and meta-analysis. 2024.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2024.1453482.","DOI":"10.3389\/fimmu.2024.1453482"},{"key":"3281_CR9","doi-asserted-by":"publisher","unstructured":"Jin L, Yu-Bo L, Qing-Bo W, et al. Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis. 2025. https:\/\/doi.org\/10.3389\/fimmu.2024.1519999.","DOI":"10.3389\/fimmu.2024.1519999"},{"key":"3281_CR10","doi-asserted-by":"publisher","unstructured":"Yu-Kai L, Song W, Yu-Shan W, et al. Portal venous and hepatic arterial coefficients predict post-hepatectomy overall and recurrence-free survival in patients with hepatocellular carcinoma: a retrospective study. 2024. https:\/\/doi.org\/10.2147\/jhc.S462168.","DOI":"10.2147\/jhc.S462168"},{"key":"3281_CR11","doi-asserted-by":"publisher","unstructured":"Qing-Bo W, Jin L, Zi-Jun Z, et al. The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and\/or right atrium: a systematic review and single-arm meta-analysis. 2025.\u00a0https:\/\/doi.org\/10.1080\/14737140.2025.2489651.","DOI":"10.1080\/14737140.2025.2489651"},{"key":"3281_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01136-2","author":"W Dong-Rui","year":"2022","unstructured":"Dong-Rui W, Xian-Lin W, Ying-Li S. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-022-01136-2.","journal-title":"Signal Transduct Target Ther"},{"key":"3281_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","author":"X Yi","year":"2020","unstructured":"Yi X, Dihua Y. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2020. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753.","journal-title":"Pharmacol Ther."},{"key":"3281_CR14","doi-asserted-by":"publisher","unstructured":"Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdw168.","DOI":"10.1093\/annonc\/mdw168"},{"key":"3281_CR15","doi-asserted-by":"publisher","unstructured":"Yuan Z, Meng-Jie L, Lei Z, et al. High mobility group A1 (HMGA1) promotes the tumorigenesis of colorectal cancer by increasing lipid synthesis. 2024. https:\/\/doi.org\/10.1038\/s41467-024-54400-0.","DOI":"10.1038\/s41467-024-54400-0"},{"key":"3281_CR16","doi-asserted-by":"publisher","unstructured":"Longzheng X, Linda O, Jinguan L, et al. The cancer metabolic reprogramming and immune response. 2021. https:\/\/doi.org\/10.1186\/s12943-021-01316-8.","DOI":"10.1186\/s12943-021-01316-8"},{"key":"3281_CR17","doi-asserted-by":"publisher","unstructured":"Oleg S, Alexandra D, Olga F, et al. Linking metabolic reprogramming, plasticity and tumor progression. 2021. https:\/\/doi.org\/10.3390\/cancers13040762.","DOI":"10.3390\/cancers13040762"},{"key":"3281_CR18","doi-asserted-by":"publisher","unstructured":"Rishab R, Mauricio SC, Hampartsoum BB, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. 2018. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.004.","DOI":"10.1016\/j.pharmthera.2018.11.004"},{"key":"3281_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2017.04.003","author":"EB Kathryn","year":"2017","unstructured":"Kathryn EB, Stephanie OD, Jeffrey CR. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.04.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3281_CR20","doi-asserted-by":"publisher","unstructured":"Fusheng Z, Haiyang L, Meiqi D, et al. Crosstalk among m(6)A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01304-5.","DOI":"10.1186\/s13045-022-01304-5"},{"key":"3281_CR21","doi-asserted-by":"publisher","unstructured":"Yang X, Deng B, Zhao W, et al. FABP5 lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.029.","DOI":"10.1016\/j.jhep.2024.09.029"},{"key":"3281_CR22","doi-asserted-by":"publisher","unstructured":"Dehai W, Congyi Z, Guanqun L, et al. Targeting uridine-cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma. 2022. https:\/\/doi.org\/10.1186\/s11658-022-00403-y.","DOI":"10.1186\/s11658-022-00403-y"},{"key":"3281_CR23","doi-asserted-by":"publisher","unstructured":"Sangro B, Chan S, Kelley R, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. 2024;35(5):448\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.005.","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"3281_CR24","doi-asserted-by":"publisher","unstructured":"Sangro B, Galle P, Kelley R, et al. Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. 2024;42(23):2790\u201399. https:\/\/doi.org\/10.1200\/jco.23.01462.","DOI":"10.1200\/jco.23.01462"},{"key":"3281_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","author":"H Douglas","year":"2011","unstructured":"Douglas H, Robert AW. Hallmarks of cancer: the next generation. Cell. 2011. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"5","key":"3281_CR26","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"R DeBerardinis","year":"2016","unstructured":"DeBerardinis R, Chandel N. Fundamentals cancer metabolism. Sci Adv. 2016;2(5):e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200.","journal-title":"Sci Adv"},{"key":"3281_CR27","doi-asserted-by":"publisher","unstructured":"Daniela S, Yang J, Iris M-Q, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. 2017. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.007.","DOI":"10.1053\/j.gastro.2017.06.007"},{"key":"3281_CR28","doi-asserted-by":"publisher","unstructured":"Chunhong Z, Liangtao Z, Jae-Kwang Y, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. 169(7). https:\/\/doi.org\/10.1016\/j.cell.2017.05.035","DOI":"10.1016\/j.cell.2017.05.035"},{"key":"3281_CR29","doi-asserted-by":"publisher","unstructured":"Padmanee S, Bilal AS, Swetha A, et al. Next decade immune checkp therapy. 2021. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1680.","DOI":"10.1158\/2159-8290.Cd-20-1680"},{"key":"3281_CR30","doi-asserted-by":"publisher","unstructured":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma. J Cell. 169(7). https:\/\/doi.org\/10.1016\/j.cell.2017.05.046","DOI":"10.1016\/j.cell.2017.05.046"},{"key":"3281_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","author":"LT Suzanne","year":"2015","unstructured":"Suzanne LT, Charles GD, Drew MP. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001.","journal-title":"Cancer Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03281-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:10:18Z","timestamp":1756390218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03281-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3281"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03281-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,8,24]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there were no commercial or financial relationships that could be construed as potential conflicts of interest during the conduct of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Clinical trial number: not applicable. The data used in this study is sourced from the publicly available database and is de-identified. No additional ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"1607"}}